Recombinant sCD40L (Toralizumab Biosimilar) antibody

Catalog No. ABIN7072676

The Mouse Chimeric anti-sCD40L (Toralizumab Biosimilar) antibody has been validated for BR and IF. It is suitable to detect sCD40L (Toralizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant sCD40L (Toralizumab Biosimilar) antibody (ABIN7072676)

Target: sCD40L (Toralizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Chimeric

Conjugate: This sCD40L (Toralizumab Biosimilar) antibody is un-conjugated

Application: Blocking Reagent (BR), Immunofluorescence (IF)

Clone: IDEC-131

Product Details anti-sCD40L (Toralizumab Biosimilar) Antibody

Purpose: Anti-CD154 [IDEC-131 (Toralizumab)], Mouse IgG1, kappa

Specificity: This antibody is a non agonistic antibody specifc for human CD40 ligand.

Characteristics:

Original Species of Ab: Mouse

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogen: The original monoclonal antibody was generated by immunization with a soluble fusion protein of human gp39 (gp39-CD8).

Isotype: IgG1 kappa

Application Details

Application Notes: This antibody binds CD154 with an binding affinity of Kd = 5.6 nM for theoriginally characterized antibody (Brams et al., 2001)/ Phase I clinical trials of the antibody in pateints with systemic lupus ezythematoses revealed that a single intravenous infusion at doses of 0.05-15.0 mg/kg is safe and well tolerated in patients. (Davis et al., 2001). Although, no further development for this indication has been reported since the disclosure of disappointing phase II results in April 2000. In January 2001, phase II trials in psoriasis and idiopathic thrombocytopenic purpura (ITP) were initiated. By january 2002, a phase II trial in Crohn's disease was also ongoing. (Dumont FJ, 2002) Ab IDEC-131 was tested alone and in combination with rapamycin and DST for its ability to inhibit rhesus MLRs and it was seen that therapy with IDEC-131, rapamycin, and DST induced long-term allograft survival without intermittent acute rejection.(He Xu et, al., 2003) IDEC-131 was also used in a comparative study using 3 monoclonal antibodies αCD40 (2C10R4) and αCD154 (5C8H1 and IDEC-131 to check CD40/CD154 T cell costimulation pathway in a non-human primate cardiac allotransplant model (O'Neill et al., 2017) Other suitable use in ELISA, FC, IF, IP.

Comment:

This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for sCD40L (Toralizumab Biosimilar)

Target: sCD40L (Toralizumab Biosimilar)

Target Type: Biosimilar

Background: CD40L, gp39, TRAP, Tumor necrosis factor ligand superfamily member 5, TNFSF5, T-cell antigen Gp39, TNF-related activation protein, TNF-related activation protein

UniProt: P29965